A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis (COAST-W)
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Study Start Date: April 2016
Actual Primary Completion Date: May 18, 2018
Estimated Study Completion Date: January 31, 2019
Arm:
- Experimental: Q2W Ixekizumab
- Experimental: Q4W Ixekizumab
- Placebo Comparator: Placebo
| Category | Value |
|---|---|
| Date last updated at source | 2018-07-04 |
| Study type(s) | Interventional |
| Expected enrolment | 300 |
| Study start date | 2016-04-01 |
| Estimated primary completion date | 2018-05-18 |